Release Date: March 30, 2018
Expiration Date: March 30, 2019
Media: Internet - based
Anticoagulant therapy plays a vital role in treating patients and preventing serious and potentially fatal complications that result from venous thromboembolism and atrial fibrillation. Direct acting oral anticoagulants (DOACs) offer several advantages over traditional vitamin K antagonist therapy with a more predictable anticoagulant response, fewer drug interactions, and significantly less risk of hemorrhagic stroke when compared to warfarin; however, in the past, the absence of a clear, effective reversal strategy was a concern with the new oral anticoagulant agents.
This Best Practice® program will review the efficacy and safety of new and emerging anticoagulation reversal agents as well as the recommended strategies for DOAC reversal. Incorporation of individual patient-specific factors will be addressed and patient cases will be used to exemplify implementation of reversal strategies. Throughout the program, we hope that you will take advantage of all the opportunities to interact with our faculty to ensure that your most pressing clinical questions are answered.
Instructions for This Activity and Receiving Credit
This educational activity is intended for hospitalists, residents, surgeons, anesthesiologists, and other hospital-based providers who care for patients requiring DOAC and/or reversal agents.
At the conclusion of this activity, you should be better prepared to:
Charles V. Pollack, Jr, MA, MD, FACEP, FAAEM, FAHA, FESC, FCPP
Associate Provost for Innovation in Education, Thomas Jefferson University
Director, Jefferson Institute of Emerging Health Professions
Director, The Lambert Center for the Study of Medicinal Cannabis and Hemp
Associate Dean for CME and Strategic Partner Alliances, Thomas Jefferson University
Professor and Senior Advisor for Interdisciplinary Research and Clinical Trials
Department of Emergency Medicine, Sidney Kimmel Medical College of Thomas Jefferson University
Disclosure: Grants/Research Support: AstraZeneca, Boehringer Ingelheim, CSL Behring, Daiichi Sankyo, Janssen, Portola; Consultant: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Janssen, Portola, ProvepharmFaculty
Steven Deitelzweig, MD, MMM, SFHM, FACP, FACC
Medical Director of Regional Business Development, System Chairman, Hospital Medicine, Professor of Medicine
Ochsner Clinical School
New Orleans, Louisiana
Disclosure: Grants/Research Support: Bristol-Myers Squibb, Pfizer, Portola; Consultant: Bristol-Myers Squibb, Janssen, Pfizer, Portola
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Physicians’ Education Resource®, LLC
2 Clarke Drive
Cranbury, NJ 08512
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
Minimum System Requirements (Mac OS)
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018